medigraphic.com

2014, Number 3

<< Back Next >>

Rev Cuba Endoc 2014; 25 (3)

Drug treatment of Cushing's syndrome

Robles TE, Leal CL, Díaz SC

Language: Spanish
References: 43
Page: 206-215
PDF size: 113.08 Kb.


ABSTRACT

Although the drug treatment is not a first line therapy for endogenous hypercortisolism, it plays a key role in certain patients suffering Cushing's syndrome. Several drugs may be used in isolation or in combination. Ketoconazol is a useful, economic, safe and efficacious option at long term. A review was made of drugs with best results, doses, efficacy, adverse effects and perspectives, taking into account clinical assays in which they have been used.


REFERENCES

  1. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). 1932. Obes Res. 1994;2(5):486-508.

  2. Trainer PJ, Besser M. Cushing’s syndrome: therapy directed at the adrenal glands. Endocrinol Metab Clin North Am. 1994;23:571-84.

  3. Leal-Cerro A, Soto Moreno A, Angel Mangas M, León Justel A, Webb S. Tratamiento farmacológico y seguimiento del Síndrome de Cushing. Endocrinol Nutr. 2009;56(4):187-94.

  4. Horgan FH, Laufgraben M. Medical management of Cushing’s Syndrome. Expert Rev Endocrinol Metab. 2013;8(2):183-93.

  5. Pont A, Williams PL, Loose DS, Feldman D, Reitz RE, Bochra C, et al. Ketoconazole blocks adrenal steroid synthesis. Ann Intern Med. 1982;97(3):370-2.

  6. Pont A, Williams PL, Azhar S, Reitz RE, Bochra C, Smith ER, et al. Ketoconazole blocks testosterone synthesis. Arch Intern Med. 1982;142(12):2137-40.

  7. Feldman D. Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis. Endocr Rev. 1986;7(4):409-20.

  8. Liu JK, Fleseriu M, Delashaw JB Jr, Ciric IS, Couldwell WT. Treatment options for Cushing disease after unsuccessful transsphenoidal surgery. Neurosurg Focus. 2007;23(3):E8.

  9. Rizk A, Honegger J, Milian M, Psaras T. Treatment Options in Cushing’s Disease. Clin Med Insights Oncol. 2012;6:75-84.

  10. Mancini T, Porcelli T, Giustina A. Treatment of Cushing disease: overview and recent findings. Ther Clin Risk Manag. 2010;6:505-16.

  11. Miller JW, Crapo L. The medical treatment of Cushing’s syndrome. Endocr Rev. 1993;14(4):443-58.

  12. Castinetti F, Morange I, Jaquet P, Conte-Devolx B, Brue T. Ketoconazole revisited: a preoperative or postoperative treatment in Cushing’s disease. Eur J Endocrinol. 2008;158:91-9.

  13. Espinosa-Cárdenas PE, Espinosa de los Monteros-Sánchez AL, Mercado M, Sosa- Eroza E. Ketoconazol en el tratamiento de la enfermedad de Cushing. Rev Endocrinol y Nutr. Oct-dic 2013;21(4):164-70.

  14. Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med. 1987;317(13):812-8.

  15. Lake-Bakaar G, Scheuer PJ, Sherlock S. Hepatic reactions associated with ketoconazole in the United Kingdom. Br Med J (Clin Res Ed). 1987;294(6569):419-22.

  16. Janssen PAJ, Symoens JE. Hepatic reactions during ketoconazole treatment. Am J Med. 1983;74:80-5.

  17. Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, et al. Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab. 2008;93(7):2454-62.

  18. Liddle GW, Island D, Lance EM, Harris AP. Alterations of adrenal steroid patterns in man resulting from treatment with a chemical inhibitor of 11 betahydroxylation. J Clin Endocrinol Metab. 1958;18(8):906-12.

  19. Gower DB. Modifiers of steroid-hormone metabolism: a review of their chemistry, biochemistry and clinical applications. J Steroid Biochem. 1974;5(5):501-23.

  20. Sonino N, Boscaro M. Medical therapy for Cushing’s disease. Endocrinol Metab Clin North Am. 1999;28(1):211-22.

  21. Verhelst JA, Trainer PJ, Howlett TA, Perry L, Rees LH, Grossman AB, et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing’s syndrome. Clin Endocrinol (Oxf). 1991;35:169-78.

  22. Jeffcoate WJ, Rees LH, Tomlin S, Jones AE, Edwards CR, Besser GM. Metyrapone in long-term management of Cushing’s disease. Br Med J. 1977;2(6081):215-7.

  23. Schulte HM, Benker G, Reinwein D, Sippell WG, Allolio B. Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing’s syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab. 1990;70(5):1426-30.

  24. Greening JE, Brain CE, Perry LA, Mushtaq I, Sales Marques J, Grossman AB, et al. Efficient short-term control of hypercortisolaemia by low-dose etomidate in severe paediatric Cushing’s disease. Horm Res. 2005;64(3):140-3.

  25. Heyn J, Geiger C, Hinske CL, Briegel J, Weis F. Medical suppression on hypercortisolemia in Cushing’s syndrome with particular consideration of etomidate. Pituitary. 2012;15(2):117-25.

  26. Fleseriu M, Petersenn S. Medical management of Cushing’s disease: what is the future? Pituitary. 2012;15(3):330-41.

  27. Krakoff J, Koch CA, Calis KA, Alexander RH, Nieman LK. Use of a parenteral propylene glycol-containing etomidate preparation for the long-term management of ectopic Cushing’s syndrome. J Clin Endocrinol Metab. 2001;86(9):4104-8.

  28. Luton JP, Mahoudeau JA, Bouchard PH, Thieblot P, Hautecouverture M, Simon D, et al. Treatment of Cushing’s disease by O,p’DDD. Survey of 62 cases. N Eng J Med. 1979;300(9):459-64.

  29. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366(23):2189-97.

  30. Veystman I, Nieman L, Fojo T. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol. 2009;27(27):4619-29.

  31. Lim MC, Tan YO, Chong PY, Cheah JS. Treatment of adrenal cortical carcinoma with mitotane outcome and complications. Ann Acad Med Singapore. 1990;19:540- 4.

  32. Marshall JS, Tompkins LS. Effect of o,p’-DDD and similar compounds on thyroxine binding globulin. J Clin Endocrinol Metab. 1968;28:386-92.

  33. Lacroix A. Approach to the patient with adrenocortical carcinoma. J Clin Endocrinol Metab. 2010;95(11):4812-22.

  34. Dexter RN, Fishman LM, Ney RL, Liddle GW. Inhibition of adrenal corticosteroid synthesis by aminoglutethimide. Studies on the mechanism of action. J Clin Endocrinol Metab. 1967;27:473-80.

  35. Camacho AM, Cash R, Brough AJ, Wilroy RS. Inhibition of adrenal steroidogenesis by amino-glutethimide and the mechanism of action. JAMA. 1967;202:20-6.

  36. Philbert M, Laudat MH, Laudat P, Bricaire H. Clinical and biological study of an inhibitor of adrenocortical hormone synthesis: aminoglutethinide. Ann Endocrinol (Paris). 1968;29(2):189-210.

  37. Schteingart DE, Cash R, Conn JW. Aminoglutethimide and metastatic adrenal cancer. Maintained reversal (six months) of Cushing’s syndrome. JAMA. 1966;198:1007-10.

  38. Santen RJ, Misbin RI. Aminoglutethimide: review of pharmacology and clinical use. Pharmacotherapy. 1981;12:95-120.

  39. Riedl M, Maier C, Zettinig G, Nowotny P, Schima W, Luger A. Long term control of hypercortisolism with fluconazole: case report and in vitro studies. Eur J Endocrinol. 2006;154(4):519-24.

  40. Castinetti F, Fassnacht M, Johanssen S. Merits and pitfalls of mifepristone in Cushing’s síndrome. Eur J Endocrinol. 2009;160:1003-10.

  41. Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C; on behalf of the SEISMIC Study investigators. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s síndrome. J Clin Endocrinol Metab. 2012;97:2039-49.

  42. Bertagna X, Guignat L. Approach to the Cushing’s disease patient with persistent/recurrent hypercortisolism after pituitary surgery. J Clin Endocrinol Metab. April 2013;98(4):1307-8.

  43. Kamenicky P, Droumaguet C, Salenave S, Blanchard A, Jublanc C, Gautier JF, et al. Mitotane, metyrapone and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing’s syndrome. J Clin Endocrinol Metab. 2011;96:2796-804.




2020     |     www.medigraphic.com